Year: 2012
Type: review
Abstract: Clinical and epidemiological featuresSquamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer worldwide, affecting 600,000 new patients each year.In the United States, 50,000 new cases are diagnosed, and nearly 10,000 deaths are attributable to this disease annually.Despite their common origin in the squamous mucosa of the upper aerodigestive tract, there are several sources for the heterogeneity of HNSCC that complicate their consideration as a single disease entity.Anatomically, the head and neck region consists of several distinct structures (e.g., lip, tongue, nasopharynx, oropharynx, larynx, hypopharynx) with distinct microscopic features and lymphatic and venous drainage.As a result, treatment approaches and outcomes vary significantly among the different subsites.In addition, etiologic risk factors vary among the different subsites, and HNSCC can occur in young patients without any known risk factors.Biologic heterogeneity independent of subsite has been suggested by molecular analyses that have uncovered distinct classes of HNSCC with unique mRNA expression profiles or patterns of DNA copy number alterations that correlate with clinical behavior (1-4).Although the most important risk factors are tobacco use and alcohol consumption, infection with high-risk types of human papilloma viruses (HPVs) has also been recognized as an increasingly important risk factor, particularly for oropharyngeal squamous cell carcinoma (OPSCC).Importantly, survival for patients with HPV-positive OPSCC is significantly better than for HPV-negative cancers, irrespective of treatment modality (5-8).Possible explanations include both host-intrinsic factors (healthier patients with fewer comorbidities) and tumor-intrinsic factors (distinct genetic pathogenesis yielding enhanced treatment sensitivity).The relatively good prognosis of HPV-related cancers highlights an unfortunate paradox -despite improvements in outcome for patients with oropharynx cancers, little or no improvement has been observed for patients with HPV-negative tumors over the past 30 years (9).This fact is attributable at least in part to our limited understanding of molecular pathways that both promote HSNCC pathogenesis and can be targeted therapeutically.
DOI: 10.1172/jci59889
Authors: S. Michael Rothenberg, Leif W. Ellisen
Institutions: Harvard University, Massachusetts General Hospital
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2096906078
